Lucira Health up as Canada authorizes COVID, flu test

Lucira Health

11/08/2022 13:34

** Shares of infectious disease test maker Lucira Health
 LHDX.O  rise ~10.6% to $3.35 premarket
    ** Health Canada grants authorization for emergency use and
commercialization of co's at-home test for COVID and flu
 urn:newsml:reuters.com:*:nFWN2ZN4DZ
    ** The rapid molecular test delivers results in up to 30
minutes from one shallow nasal swab
    ** Up to Wednesday's close, stock fell over 64% so far this
year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))